Scholarlink

Purpose <p>Combined lung–liver transplant (CLLT) is a complex yet life-saving procedure for patients with simultaneous end-stage lung and liver disease. Given the geographical allocation change to the lung allocation score (LAS) in 2017 and the recent SARS-CoV-2 outbreak in 2019, we aim to provide an updated analysis of the patient selection and outcomes of CLLTs.</p> Methods <p>The UNOS registry was used to identify all patients who underwent CLLT between January 2014 and June 2023. To account for the changes made to LAS in 2017, baseline characteristics and outcomes were compared between era 1 (before 2017) and era 2 (after 2017). Risk factors for mortality were analyzed using the Cox regression hazard models. Recipient survival of up to 3 years was analyzed using the Kaplan–Meier method.</p> Results <p>117 CLLTs were performed (77.8% in era 2). Donor organs experienced significantly longer ischemic times (<i>p</i> = 0.039) and traveled longer distances (<i>p</i> = 0.025) in era 2. However, recipient (<i>p</i> = 0.79) and graft (<i>p</i> = 0.41) survival remained comparable at up to 3&#xa0;years post-transplant between eras. CLLTs demonstrated similar long-term survival to isolated lung transplants (<i>p</i> = 0.73). Higher recipient LAS was associated with an increased mortality risk (HR 1.14, <i>p</i> = 0.034)<i>.</i> Recipient diagnosis of idiopathic pulmonary fibrosis carried a 5.03-fold risk of mortality (<i>p</i> = 0.048) compared to those with cystic fibrosis.</p> Conclusion <p>In the post-2017 LAS change era, CLLTs are increasingly performed with comparable outcomes to isolated lung transplants. A careful, multidisciplinary approach to patient selection and management remains paramount to optimizing outcomes for this rare patient population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

National Trends and Outcomes of Combined Lung–Liver Transplantation: An Analysis of the UNOS Registry

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月25日

查看全文
  • Brian J. Bao,
  • Ye In Christopher Kwon,
  • Emily G. Dunbar,
  • Zachary Rollins,
  • Jay Patel,
  • Matthew Ambrosio,
  • David A. Bruno,
  • Vipul Patel,
  • Walker A. Julliard,
  • Vigneshwar Kasirajan,
  • Zubair A. Hashmi

摘要

Purpose

Combined lung–liver transplant (CLLT) is a complex yet life-saving procedure for patients with simultaneous end-stage lung and liver disease. Given the geographical allocation change to the lung allocation score (LAS) in 2017 and the recent SARS-CoV-2 outbreak in 2019, we aim to provide an updated analysis of the patient selection and outcomes of CLLTs.

Methods

The UNOS registry was used to identify all patients who underwent CLLT between January 2014 and June 2023. To account for the changes made to LAS in 2017, baseline characteristics and outcomes were compared between era 1 (before 2017) and era 2 (after 2017). Risk factors for mortality were analyzed using the Cox regression hazard models. Recipient survival of up to 3 years was analyzed using the Kaplan–Meier method.

Results

117 CLLTs were performed (77.8% in era 2). Donor organs experienced significantly longer ischemic times (p = 0.039) and traveled longer distances (p = 0.025) in era 2. However, recipient (p = 0.79) and graft (p = 0.41) survival remained comparable at up to 3 years post-transplant between eras. CLLTs demonstrated similar long-term survival to isolated lung transplants (p = 0.73). Higher recipient LAS was associated with an increased mortality risk (HR 1.14, p = 0.034). Recipient diagnosis of idiopathic pulmonary fibrosis carried a 5.03-fold risk of mortality (p = 0.048) compared to those with cystic fibrosis.

Conclusion

In the post-2017 LAS change era, CLLTs are increasingly performed with comparable outcomes to isolated lung transplants. A careful, multidisciplinary approach to patient selection and management remains paramount to optimizing outcomes for this rare patient population.